309 related articles for article (PubMed ID: 29538138)
1. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
Borghi C; Ventura F
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
[No Abstract] [Full Text] [Related]
2. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
3. Is glycemic control a quinidine-like intervention?
Bloomgarden ZT
J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
[No Abstract] [Full Text] [Related]
4. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Shehadeh N; Raz I; Nakhleh A
Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
[No Abstract] [Full Text] [Related]
5. Is there a U-shaped curve of A1c versus mortality?
Bloomgarden ZT; Drexler A
J Diabetes; 2012 Jun; 4(2):107-8. PubMed ID: 22443259
[No Abstract] [Full Text] [Related]
6. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
Low Wang CC; Everett BM; Burman KD; Wilson PWF
Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
[No Abstract] [Full Text] [Related]
7. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
8. An interview with the authors of "Is there a U-shaped curve of A1c vs. mortality?".
Bloomgarden Z; Drexler A
J Diabetes; 2012 Jun; 4(2):109. PubMed ID: 22583822
[No Abstract] [Full Text] [Related]
9. The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.
Fatima S; Jameel A; Ayesha F; Menzies DJ
Clin Cardiol; 2017 Nov; 40(11):970-973. PubMed ID: 28841228
[TBL] [Abstract][Full Text] [Related]
10. SGLT2i: beyond the glucose-lowering effect.
Ni L; Yuan C; Chen G; Zhang C; Wu X
Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
[TBL] [Abstract][Full Text] [Related]
11. New anti-diabetic agents: major advances with unanswered questions.
Sabouret P; Bocchino PP; Biondi-Zoccai G
Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
13. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
14. Diabetic Kidney Disease.
Tong L; Adler SG
Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
[No Abstract] [Full Text] [Related]
15. [Intensive therapy in type 2 diabetes. More damage than benefit?].
Einecke D
MMW Fortschr Med; 2008 Jun; 150(26-27):12-4. PubMed ID: 18681224
[No Abstract] [Full Text] [Related]
16. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Inzucchi SE; Kosiborod M; Fitchett D; Wanner C; Hehnke U; Kaspers S; George JT; Zinman B
Circulation; 2018 Oct; 138(17):1904-1907. PubMed ID: 30354665
[No Abstract] [Full Text] [Related]
17. The residual cardiorenal risk in type 2 diabetes.
Giugliano D; Maiorino MI; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683
[TBL] [Abstract][Full Text] [Related]
18. [Is it necessary to call into question the benefits of glycemic control in type-2 diabetes?].
Scheen AJ
Rev Med Suisse; 2014 Aug; 10(439):1531-2. PubMed ID: 25272668
[No Abstract] [Full Text] [Related]
19. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin A1c in hemodialysis patients: should one size fit all?
Ix JH
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1539-41. PubMed ID: 20671219
[No Abstract] [Full Text] [Related]
[Next] [New Search]
